Back

A multicenter, randomized, double-blind, placebo-controlled, parallel group study on the safety and efficacy of istaroxime for pre-cardiogenic shock

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Late-breaking science in acute heart failure Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Jan Biegus

Institute of Heart Diseases, Wroclaw (Poland)

6 More presentations in this session

Presentation thumbnail
Discussant panel
Presentation thumbnail
Kidney function trajectories before and after heart failure hospitalization in heart failure with reduced ejection fraction: findings from clinical trials and real-world data
Professor N. Girerd (Nancy, FR)
Slides Video
Presentation thumbnail
Sodium chloride vs. glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure
Associate Professor J. Biegus (Wroclaw, PL)
Slides Video
Presentation thumbnail
Combination oral acetazolamide and intravenous furosemide on acute decompensated heart failure
Mrs I. Farissa (Semarang, ID)
Slides Video
Presentation thumbnail
Impact of a urinary-sodium driven algorithm to optimize natriuresis in patients with ADHF: the FASTR trial
Associate Professor K. Damman (Groningen, NL)
Slides Video

Access the full session

Session thumbnail
Late-breaking science in acute heart failure
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Inotropes and vasopressors
thumbnail
Congress Presentation
Levosimendan in patients with cardiogenic shock refractory to dobutamine weaning
thumbnail
Congress Presentation
Cardiogenic shock: the next frontier

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources